Evidence map›Paper›PMID 30268825›Full record

ArticleEuropean journal of medicinal chemistry2018

Modified carbazoles destabilize microtubules and kill glioblastoma multiform cells.

Philippe Diaz, Eric Horne, Cong Xu, Ernest Hamel, Michael Wagenbach, Ravil R Petrov, Benjamin Uhlenbruck, Brian Haas, Parvinder Hothi, Linda Wordeman and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of medicinal chemistry, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Carbazole scaffolds in cancer therapy: a review from 2012 to 2018.Journal of enzyme inhibition and medicinal chemistry · 2019
    Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Philippe DiazDepartment of Biomedical and Pharmaceutical Sciences, The University of Montana, 32 Campus Drive, Missoula, MT, 59812, USA; DermaXon LLC, 32 Campus Drive, Missoula, MT, 59812, USA. Electronic address: Philippe.diaz@umontana.edu.
Eric HorneStella Therapeutics, Inc., Pacific Northwest Research Institute, 720 Broadway, Seattle, WA, 98122, USA.
Cong XuDepartment of Pharmacology (CX, BH and NS), Department of Physiology and Biophysics (MW and LW), Department of Psychiatry and Behavioral Sciences (NS), The University of Washington, Seattle, WA, 98195, USA.
Ernest HamelScreening Technologies Branch (EH) and Computational Drug Development Group (RG), Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, Frederick National Laboratory for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, 21702, USA.
Michael WagenbachDepartment of Pharmacology (CX, BH and NS), Department of Physiology and Biophysics (MW and LW), Department of Psychiatry and Behavioral Sciences (NS), The University of Washington, Seattle, WA, 98195, USA.
Ravil R PetrovDepartment of Biomedical and Pharmaceutical Sciences, The University of Montana, 32 Campus Drive, Missoula, MT, 59812, USA.
Benjamin UhlenbruckDepartment of Biomedical and Pharmaceutical Sciences, The University of Montana, 32 Campus Drive, Missoula, MT, 59812, USA.
Brian HaasDepartment of Pharmacology (CX, BH and NS), Department of Physiology and Biophysics (MW and LW), Department of Psychiatry and Behavioral Sciences (NS), The University of Washington, Seattle, WA, 98195, USA.
Parvinder HothiIvy Center for Advance Brain Tumor Treatment, Swedish Neuroscience Institute, 550 17th Ave, Seattle, WA, 98122, USA.
Linda WordemanDepartment of Pharmacology (CX, BH and NS), Department of Physiology and Biophysics (MW and LW), Department of Psychiatry and Behavioral Sciences (NS), The University of Washington, Seattle, WA, 98195, USA.
Rick GussioScreening Technologies Branch (EH) and Computational Drug Development Group (RG), Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, Frederick National Laboratory for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, 21702, USA.
Nephi StellaStella Therapeutics, Inc., Pacific Northwest Research Institute, 720 Broadway, Seattle, WA, 98122, USA; Department of Pharmacology (CX, BH and NS), Department of Physiology and Biophysics (MW and LW), Department of Psychiatry and Behavioral Sciences (NS), The University of Washington, Seattle, WA, 98195, USA. Electronic address: nstella@uw.edu.
University of Washington · USUniversity of Montana · USNational Institutes of Health · USPacific Northwest Diabetes Research Institute · USSwedish Medical Center · US

Funding

Surveillance genome sequencing to detect SARS-CoV-2 virus variants in MontanaP20GM103546 · NIGMS · UNIVERSITY OF MONTANA · PI BOWLER, BRUCE E · 2012 to 2021
$19.2M
Microtubule Dynamics and Chromosome SegregationR01GM069429 · NIGMS · UNIVERSITY OF WASHINGTON · PI WORDEMAN, LINDA · 2004 to 2020
$5.6M
Core Laboratory for Neuromolecular ProductionP30NS055022 · NINDS · UNIVERSITY OF MONTANA · PI THOMPSON, CHARLES MARK · 2008 to 2013
$4.2M
Cannabinoid Signaling System in Microglial CellsR01DA014486 · NIDA · UNIVERSITY OF WASHINGTON · PI STELLA, NEPHI · 2001 to 2016
$4.2M
Differential response of glioblastomas to microtubule targeting agentsR01CA244213 · NCI · UNIVERSITY OF WASHINGTON · PI STELLA, NEPHI · 2020 to 2024
$1.5M
Novel microtubule-targeting agents for the treatment of glioblastoma multiformR21NS106924 · NINDS · UNIVERSITY OF WASHINGTON · PI STELLA, NEPHI · 2018 to 2019
$411k
Targeting a new GPCR to treat glioblastomasR43CA165452 · NCI · STELLA THERAPEUTICS, INC. · PI HORNE, ERIC ANDREW · 2012 to 2013
$288k
Selective inhibition of CYP26A1 in the skin for the treatment of ichthyosisR41AR069416 · NIAMS · DERMAXON, LLC · PI ASTRUC DIAZ, FANNY · 2016 to 2016
$216k
NCI NIH HHS R01 CA244213NCI NIH HHS R43 CA165452NIAMS NIH HHS R41 AR069416NIDA NIH HHS R01 DA014486NIGMS NIH HHS P20 GM103546NIGMS NIH HHS R01 GM069429NINDS NIH HHS P30 NS055022NINDS NIH HHS R21 NS106924
6 · The paper itself

Abstract

Small molecules that target microtubules (MTs) represent promising therapeutics to treat certain types of cancer, including glioblastoma multiform (GBM). We synthesized modified carbazoles and evaluated their antitumor activity in GBM cells in culture. Modified carbazoles with an ethyl moiety linked to the nitrogen of the carbazole and a carbonyl moiety linked to distinct biaromatic rings exhibited remarkably different killing activities in human GBM cell lines and patient-derived GBM cells, with IC

Indexed as

Antineoplastic AgentsCarbazolesCell Line, TumorCell ProliferationCell SurvivalDose-Response Relationship, DrugDrug Screening Assays, AntitumorGlioblastomaHumansMicrotubulesMolecular Docking SimulationMolecular StructureStructure-Activity RelationshipAntineoplastic AgentsCarbazolesCarbazoleColchicineGliomasMicrotubules

Identifiers

PMID30268825
PMCPMC6690746
OpenAlexW2890109436

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.